Risk factor
Strong trading liquidity
Profitability factor
Overvalued vs peers
About
Tofflon Science and Technology Group Co., Ltd., originally established in 1993 as Shanghai Tofflon Science and Technology Co., Ltd. and headquartered in Shanghai, China, serves as a global purveyor of sophisticated equipment for the pharmaceutical and biotechnology sectors. The company's diverse offerings encompass specialized machinery for injectable drug manufacturing, including automated systems for solution preparation, aseptic filling lines tailored for ampoules, vials, syringes, and powders, along with freeze dryers featuring automatic loading capabilities, barrier systems, and plastic packaging machines. Beyond equipment, Tofflon also supplies active pharmaceutical ingredients and provides essential quality control systems such as visual inspection, leak detection, and integrated combination units. Furthermore, Tofflon is a significant provider of bio-process equipment and comprehensive integrated systems. These solutions cover various stages, from medium and buffer preparation to cell/microbial cultivation, harvesting, diafiltration/ultrafiltration (DF/UF), purification, and final filling processes. The company also offers specialized laboratory services for lyophilization of injectables.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, o
Target Price
The average target price of 300171.SZ is 16.5 and suggests 0.426% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recomme